CCR8 Antibodies

Structure of CCR8

The CCR8 gene encodes a G protein-coupled receptor with a molecular weight of approximately 41 kDa. This molecular weight shows subtle differences among different mammals, mainly due to interspecific variations in the amino acid sequences of the extracellular region.

The CCR8 protein is composed of 367 amino acids and forms a typical seven-transmembrane topological structure. Its N-terminal region contains conserved glycosylation sites, and the third intracellular loop is responsible for G protein-coupled signal transduction. The second extracellular loop constitutes the chemokine binding pocket, and the key aspartic acid residue directly participates in ligand recognition. The activation mechanism of receptors involves conformational rearrangement of transmembrane helices, thereby triggering downstream signaling pathways.

Fig. 1 Protein–protein interaction with CCR8.¹

Key structural properties of CCR8:

• Typical configuration of the seven-fold transmembrane helix topology
• Conserved asparty-tyrosine structural motifs are used for signal transduction
• The second extracellular loop forms chemokine-specific binding pockets

Functions of CCR8

The core function of the CCR8 gene is to regulate the migration of immune cells and inflammatory responses, and it also participates in the immune regulation process in the tumor microenvironment.

The ligand binding curve of CCR8 exhibits typical GPCR characteristics. Its high affinity binding to CCL1 enables it to initiate signal transduction even in a low-concentration chemokine environment, a feature that differs from the broad-spectrum binding patterns of other chemokine receptors.

Applications of CCR8 and CCR8 Antibody in Literature

1. Van Damme, Helena, et al. "Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy." Journal for immunotherapy of cancer 9.2 (2021): e001749. https://doi.org/10.1136/jitc-2020-001749

This study found that CCR8 is a specific marker for tumor-infiltrating Treg cells. By constructing CCR8-targeted nanobodies, Treg cells within tumors can be specifically eliminated under the mediation of NK cells, and in combination with anti-PD-1 therapy, tumor growth can be inhibited without affecting peripheral Treg cells, demonstrating good therapeutic effects and safety.

2. Sun, Ting, et al. "Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation." Journal of Experimental & Clinical Cancer Research 42.1 (2023): 253. https://doi.org/10.1186/s13046-023-02815-w

Research has found that lactic acid produced by tumor cell metabolism directly upregulates the expression of immunosuppressive genes such as CCR8 by inducing histone H3K18 lacylation. This promoted the increase of tumor-infiltrating Treg cells during CAR-T treatment, revealing that the lactate-CCR8 axis is a key mechanism for shaping the immunosuppressive microenvironment.

3. Korbecki, Jan, et al. "CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands." International journal of molecular sciences 21.20 (2020): 7619. https://doi.org/10.3390/ijms21207619

Research has found that CCR8 is one of the chemokine receptors for CC, and its ligand is CCL1. In tumors, CCR8 not only affects the proliferation and migration of cancer cells but also promotes tumor progression by recruiting regulatory T cells and other immune cells, shaping an immunosuppressive microenvironment. It is an important potential target for cancer treatment.

4. Tian, Binle, et al. "CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype." Journal of Experimental & Clinical Cancer Research 44.1 (2025): 113. https://doi.org/10.1186/s13046-025-03286-x

This study confirmed that CCR8 is highly expressed in Treg cells infiltrating liver cancer. The use of the self-developed CCR8 antagonist IPG0521m can effectively weaken the immunosuppressive function of Treg cells, thereby activating the anti-tumor activity of CD8+ T cells and NK cells, significantly inhibiting the growth of liver cancer, and providing a new basis for tumor treatment targeting CCR8.

5. Moser, Bernhard. "Chemokine receptor-targeted therapies: special case for CCR8." Cancers 14.3 (2022): 511. https://doi.org/10.3390/cancers14030511

This study indicates that CCR8, as a chemokine receptor highly expressed on tumor-suppressive Treg cells, is a highly promising new target for cancer treatment. Targeting CCR8 can specifically eliminate immunosuppressive cells within tumors, thereby enhancing anti-tumor immunity and is expected to improve the efficacy and safety of existing immune checkpoint treatments.

Creative Biolabs: CCR8 Antibodies for Research

Creative Biolabs specializes in the production of high-quality CCR8 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom CCR8 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our CCR8 antibodies, custom preparations, or technical support, contact us at email.